Incannex Healthcare announced its IHL-42X won the MedTech Breakthrough Award for Best New Technology Solution for Drug Development, highlighting clinical progress in obstructive sleep apnea.
Key takeaways
IHL-42X won 'Best New Technology Solution for Drug Development' at MedTech Breakthrough Awards, validating clinical progress.
Phase 2 RePOSA trial showed statistically significant reductions in apnea-hypopnea index and improved oxygenation and sleep quality.
Award underscores Incannex's leadership in next-generation drug development for obstructive sleep apnea.
Recognition comes as Incannex advances IHL-42X toward late-stage development and explores strategic opportunities.